Last reviewed · How we verify
Placebo (NaCl 0.9 % solution)
Placebo (NaCl 0.9 % solution) is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Placebo control in clinical trials, Vehicle for parenteral drug delivery. Also known as: Restricted, Liberal.
Normal saline (0.9% NaCl solution) is an inert isotonic fluid that serves as a physiological vehicle for drug delivery or fluid replacement with no active pharmacological mechanism.
Placebo (NaCl 0.9% solution) is a solution used as a control in various clinical trials, including studies for genital herpes simplex type 2, anticoagulation, and intraocular pressure. It is a saline solution with no known oligosaccharide or heparin properties, as indicated by its modality and synonyms in ChEMBL.
At a glance
| Generic name | Placebo (NaCl 0.9 % solution) |
|---|---|
| Also known as | Restricted, Liberal |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo saline contains sodium chloride at a concentration matching blood plasma osmolality, making it isotonic and suitable for intravenous or parenteral administration. It has no intrinsic therapeutic mechanism of action and is used as a control comparator in clinical trials or as a neutral vehicle for other medications. Any clinical benefit observed is attributable to placebo effect rather than pharmacological activity.
Approved indications
- Placebo control in clinical trials
- Vehicle for parenteral drug delivery
Common side effects
- Injection site reactions (rare)
- Fluid overload (with excessive volume)
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China. (PHASE3)
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (PHASE1)
- A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) (PHASE3)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (NaCl 0.9 % solution) CI brief — competitive landscape report
- Placebo (NaCl 0.9 % solution) updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Placebo (NaCl 0.9 % solution)
What is Placebo (NaCl 0.9 % solution)?
How does Placebo (NaCl 0.9 % solution) work?
What is Placebo (NaCl 0.9 % solution) used for?
Who makes Placebo (NaCl 0.9 % solution)?
Is Placebo (NaCl 0.9 % solution) also known as anything else?
What development phase is Placebo (NaCl 0.9 % solution) in?
What are the side effects of Placebo (NaCl 0.9 % solution)?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Indication: Drugs for Placebo control in clinical trials
- Indication: Drugs for Vehicle for parenteral drug delivery
- Also known as: Restricted, Liberal
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing